Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Foghorn TherapeuticsFHTX -2.19%67 PS Ratio is 12.11 as of Aug. 26, 2026, which is 11% below its 10-year median of 13.63. GuruFocus rates FHTX with a GF Score™ of 67/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 931 Biotechnology companies, Foghorn Therapeutics ranks worse than 55.85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Foghorn Therapeutics's share price is $6.675.
Foghorn Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.55. Hence, Foghorn Therapeutics's PS Ratio for today is 12.11.
The historical rank and industry rank for Foghorn Therapeutics's PS Ratio or its related term are showing as below:
FHTX'
s PS Ratio Range Over the Past 10 Years
Min: 3.64 Med: 13.63 Max: 5176
Current: 12.13
During the past 8 years, Foghorn Therapeutics's highest PS Ratio was 5176.00. The lowest was 3.64. And the median was 13.63.
FHTX's PS Ratio is ranked worse than 55.85% of 931
companies
in the Biotechnology industry
Industry Median: 9.49
vs FHTX: 12.13
During the past 12 months, the average Revenue per Share Growth Rate of Foghorn Therapeutics was 43.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 2.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 80.30% per year.
During the past 8 years, Foghorn Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 175.30% per year. The lowest was 2.10% per year. And the median was 127.50% per year.
Foghorn Therapeutics (NAS:FHTX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Foghorn Therapeutics PS Ratio Related Terms
Foghorn Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Foghorn Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Foghorn Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Foghorn Therapeutics's Share Price of today is $6.675. Foghorn Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Foghorn Therapeutics (FHTX) has a PS Ratio of 12.11 as of Aug. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Foghorn Therapeutics and its competitors. This is 11% below median its historical median of 13.63. Over the past decade, Foghorn Therapeutics' PS Ratio has ranged from 3.64 to 5,176.00. According to the industry distribution chart, Foghorn Therapeutics ranks #520 out of 931 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Foghorn Therapeutics' PS Ratio too high?
Foghorn Therapeutics' current PS Ratio of 12.11 is 11% below median its 10-year median of 13.63. Over the past 10 years, this metric has ranged from a low of 3.64 to a high of 5,176.00. The Biotechnology industry median PS Ratio is 9.49. Foghorn Therapeutics' value of 12.11 is 27.6% above this industry median. Based on the distribution chart, Foghorn Therapeutics ranks #520 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' PS Ratio compare to NWBO and FATE?
According to the Biotechnology industry distribution chart, Foghorn Therapeutics ranks #520 out of 931 companies for PS Ratio. This places Foghorn Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.49. Foghorn Therapeutics' value of 12.11 is 27.6% above this benchmark. Historically, Foghorn Therapeutics' own PS Ratio has ranged from 3.64 to 5,176.00 over the past decade. While the company's 10-year median is 13.63 vs. the industry median of 9.49, Foghorn Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foghorn Therapeutics's current PS Ratio of 12.11 is 27.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Foghorn Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foghorn Therapeutics's current PS Ratio is 12.11, which is 11% below median its own 10-year median of 13.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.68 — trading 25.5% above its estimated fair value. The current PS Ratio is 12.11, which is 11% below median its 10-year median of 13.63 and 27.6% above the Biotechnology industry median of 9.49. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current PS Ratio is 12.11 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foghorn Therapeutics (FHTX) Overvalued in 2026?
Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued.
The current stock price of $6.68 is trading 25.5% above its estimated GF Value™ of $5.32.
GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.
Key valuation signals for FHTX:
PS Ratio: 12.11 (11% below median its 10-year median of 13.63)
GF Value™: $5.32 vs. price of $6.68 (25.5% above fair value)
Industry Position: 27.6% above the Biotechnology median (#520 of 931)
No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score
Get the complete analysis for FHTX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FHTX has been successfully added to your 
